Thus, it seems reasonable to recommend that ACE inhibitors be strongly considered for patients with CAD and without contraindications, particularly those with suboptimal control of risk factors such as LDL (low-density lipoprotein) cholesterol – the very patients of interest in the ESP-CAD trial described below. The gene discussed is ACE; the disease is coronary artery disorder.